Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 31

Trial Status

Recruiting1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT06051409Phase 3Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Leukemia, Lymphoblastic, Acute, Philadelphia-PositivePh+ ALL
PrincipalinvestigatorStart date: 2023-08-31

Research Network

Collaboration Network

3 collaborators·3 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Weili Zhao, M.D., Ph.D.

Shanghai Jiaotong University School of Medicine Ruijin Hospital

Moderately Similar
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Acute, L2Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Ph+ ALL

Worked with same sponsors:

Ascentage Pharma Group Inc.Guangzhou Healthquest Pharma Co., Ltd
Collaborated on 1 trial
Similarity Score34%

Elias Jabbour, M.D.

M.D. Anderson Cancer Center

Moderately Similar
2 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Acute, L2Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Ph+ ALL

Worked with same sponsors:

Ascentage Pharma Group Inc.Guangzhou Healthquest Pharma Co., Ltd
Collaborated on 1 trial
Similarity Score34%

Cyril Salek, MD

Institute of Hematology and Blood Transfusion, Czech Republic

Related
2 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Acute, L2Ph+ ALL
Similarity Score20%

Rachel B. Salit

Fred Hutch/University of Washington Cancer Consortium

Related
4 trials

Shared therapeutic areas:

Ph+ ALL
Similarity Score10%

Allen Yeoh, M.D

National University Hospital, Singapore

Related
2 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Acute, L2
Similarity Score10%

Jiong Hu

Rui Jin Hospital, Shanghai JiaoTong University School of Medicine

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Acute, L2
Similarity Score10%

Alicia Kunin-Batson, Ph.D.

Masonic Cancer Center, University of Minnesota

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Acute, L2
Similarity Score10%

Dario Campana, M.D, PhD

National University of Singapore

Related
2 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Acute, L2
Similarity Score10%

Guillermo Sanz, Doctor

Hospital Universitario La Fe

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Acute, L2
Similarity Score10%

Wing Hang Leung, MD PhD

KK Women's and Children's Hospital, BMTCT

Related
1 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Acute, L2
Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT06051409Phase 3PrincipalInvestigator

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Leukemia, Lymphoblastic, Acute, Philadelphia-PositivePh+ ALL
Recruiting

All 1 trials loaded